Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Anil K. Rustgi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6439-6919; OpenAlex author ID A5023539776; NIH RePORTER profile ID 1868587. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 7)
Trials
0
Grants
1
Labs led
3
Collaborators
141
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 4 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper, 1 grant · 2021: 5 papers · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 20

  1. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Co-author DOI 10.1001/jamaoncol.2024.1930↗
  2. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  3. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-22-0602↗
  4. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Co-author DOI 10.1016/j.pan.2021.04.005↗
  5. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  6. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001835↗
  7. EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Last author DOI 10.1158/1940-6207.capr-21-0161↗
  8. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Last author DOI 10.1158/2159-8290.cd-20-1098↗
  9. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  10. Mechanisms Underlying Metastatic Pancreatic Cancer. First author DOI 10.1007/978-3-030-22254-3_1↗
  11. Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2017.12.004↗
  12. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  13. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  14. The TALE homeodomain transcription factor MEIS1 activates the pro-metastatic melanoma cell adhesion molecule Mcam to promote migration of pancreatic cancer cel… Last author DOI 10.1002/mc.22547↗
  15. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Co-author DOI 10.1053/j.gastro.2016.11.046↗
  16. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2016.06.005↗
  17. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Last author DOI 10.1101/gad.263327.115↗
  18. Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late? First author DOI 10.1158/1078-0432.ccr-15-2494↗
  19. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  20. Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Co-author DOI 10.1158/1541-7786.mcr-11-0399↗

Grants 1

  1. Networks for functional regulation of pancreatic acinar-ductal metaplasia and epithelial plasticity R01DK060694↗

Closest collaborators

The 25 strongest of 141 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcia Irene Canto · 6 shared papers, 2018–2024 · strength 0.60
  2. Jason Robert Pitarresi · 4 shared papers, 2019–2023 · strength 0.57
  3. Randall E. Brand · 6 shared papers, 2016–2024 · strength 0.55
  4. Michael Goggins · 6 shared papers, 2016–2024 · strength 0.55
  5. Bryson W. Katona · 4 shared papers, 2021–2024 · strength 0.48
  6. Fay Kastrinos · 4 shared papers, 2020–2024 · strength 0.46
  7. Sapna Syngal · 5 shared papers, 2016–2024 · strength 0.43
  8. Elena M. Stoffel · 5 shared papers, 2016–2024 · strength 0.43
  9. Basil S. Bakir · 5 shared papers, 2016–2023 · strength 0.43
  10. James J. Farrell · 3 shared papers, 2020–2024 · strength 0.34
  11. Koushik K. Das · 4 shared papers, 2016–2023 · strength 0.33
  12. Ralph H. Hruban · 4 shared papers, 2016–2024 · strength 0.33
  13. Elliot K. Fishman · 3 shared papers, 2020–2024 · strength 0.33
  14. Anirban Maitra · 4 shared papers, 2016–2021 · strength 0.29
  15. Alison P. Klein · 3 shared papers, 2016–2024 · strength 0.25
  16. Anne Marie Lennon · 2 shared papers, 2020–2024 · strength 0.24
  17. Maximilian Reichert · 4 shared papers, 2012–2018 · strength 0.24
  18. Jinyang Li · 2 shared papers, 2021–2023 · strength 0.24
  19. Ben Z. Stanger · 2 shared papers, 2021–2023 · strength 0.24
  20. Jin Peng He · 2 shared papers, 2018–2024 · strength 0.22
  21. Brian Matthew Wolpin · 2 shared papers, 2021–2023 · strength 0.22
  22. Shigetsugu Takano · 3 shared papers, 2016–2021 · strength 0.20
  23. Yu‐Xiao Yang · 2 shared papers, 2016–2017 · strength 0.20
  24. Christine A. Iacobuzio–Donahue · 3 shared papers, 2016–2021 · strength 0.17
  25. Amanda L. Blackford · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.